The U.S. Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), a first-in-class musc ...

With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...

The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic agonist, for the treatment of schizophrenia in adults.

Hello, Reader. For all that artificial intelligence has accomplished over the last few years, one thing it has not yet ...

The analyst team omitted antibody-drug conjugates, CAR-T therapies ... of the companies’ landmark schizophrenia treatment Cobenfy. Behind BMS, Merck faces the next greatest threat of exposure ...

Psychotic disorders are severe mental health disorders that cause abnormal thinking and perceptions. Persons with a psychotic disorder often lose touch with reality and may experience symptoms like ...

Cobenfy is a new treatment for schizophrenia used to improve ... film coated Zoloft- sertraline hydrochloride solution, concentrate. Food and Drug Administration. Depression medicines. Edinoff AN, ...

Scientists from the University of Copenhagen say they have developed a drug that decreases appetite while increasing calorie burning — without any signs of nausea. “While GLP-1-based therapies ...

Moreover, on September 26, 2024, the company announced the long-awaited approval of Cobenfy for the treatment of schizophrenia. In addition to its extremely high dividend yield of over 4% ...

GSK’s Withdrawn Blood Cancer Drug Paves Path Back to Market Blenrep reduced risk of death in trial, said British drugmaker GSK predicts annual sales of over £3 billion if approved ...

Now, there's troubling news that the malaria parasite may be gaining resistance against artemisinin, the drug most often used to try and save these young lives. Advertisement "This is the first ...